Bone Biologics (NASDAQ:BBLG) Trading Up 1.4% – Here’s What Happened

Shares of Bone Biologics Corp. (NASDAQ:BBLG) rose 1.4% on Monday . The stock traded as high as $1.44 and last traded at $1.42. Approximately 13,052 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 29,234 shares. The stock had previously closed at $1.40.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Bone Biologics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Bone Biologics Trading Up 1.4%

The company has a market cap of $2.56 million, a price-to-earnings ratio of -0.39 and a beta of 0.75. The stock has a 50 day moving average price of $1.71 and a two-hundred day moving average price of $2.03.

Bone Biologics (NASDAQ:BBLG) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.86. On average, equities analysts forecast that Bone Biologics Corp. will post -5 EPS for the current fiscal year.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.